The encouraging effectiveness of innovative HER2-targeted therapy in treating advanced HER2-low breast cancers has prompted consideration for revising the clinical classification of HER2 status in breast cancer to incorporate a HER2-low category. Here, ERBB2 is linked to breast carcinoma.